Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-588210 in advanced solid tumors
NCT04316689Phase 1Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jul 2019
- Primary completion
- Sep 2021
- Modality
- Prophylactic Vaccines, Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of S-488210/S-488211 in lung cancer, head and neck cancer (HNC), bladder cancer and 2 more, sponsored by Shionogi & Co., Ltd. Primary endpoint: Number of Participants with Adverse Events up to 16 weeks. Started Jul 2019; status: completed.
02
Drugs
S-488210/S-488211
03
Conditions
lung cancerhead and neck cancer (HNC)bladder canceresophageal cancermesothelioma
Beyond the preview
Go deeper on NCT04316689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04316689.